ロード中...
Estimation of Percentage of Patients With Fibroblast Growth Factor Receptor Alterations Eligible for Off-label Use of Erdafitinib
IMPORTANCE: When a novel drug is granted accelerated approval, both its on-label and off-label uses must be taken into account. OBJECTIVES: To estimate the potential upper bound of off-label use of erdafitinib to treat advanced cancer with fibroblast growth factor receptor gene (FGFR) alterations, c...
保存先:
| 出版年: | JAMA Netw Open |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Medical Association
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6902826/ https://ncbi.nlm.nih.gov/pubmed/31755953 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2019.16091 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|